Roivant Sciences Ltd.
An insider at 2 companies in coverage, as reported on Form 4. SEC CIK 1635088. Latest Form 4 filed Oct 6, 2026.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| Arbutus Biopharma CorpABUS | Director, 10% owner | 1 | 2026-10-01 | 2026-10-01 |
| Immunovant, Inc.IMVT | Director, 10% owner | 4 | 2023-10-02 | 2025-12-12 |
| Immunovant, Inc.IMVT | 10% owner | 8 | 2019-12-18 | 2022-10-06 |
| Arbutus Biopharma CorpABUS | 10% owner | 4 | 2017-10-16 | 2021-10-18 |
Transactions: 17
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-01 | Arbutus Biopharma CorpDirector, 10% owner | Disposition to issuer | 8,967,383 | $5.00 | $44.8m | Form 4 |
| 2025-12-12 | Immunovant, Inc.Director, 10% owner | Purchase | 16,666,666 | $21.00 | $350.0m | Form 4 |
| 2025-01-13 | Immunovant, Inc.Director, 10% owner | Purchase | 16,845,010 | $20.00 | $336.9m | Form 4 |
| 2023-10-02 | Immunovant, Inc.Director, 10% owner | Purchase | 1,526,316 | $38.00 | $58.0m | Form 4 |
| 2023-10-02 | Immunovant, Inc.Director, 10% owner | Grant or award | 4,473,684 | $38.00 | $170.0m | Form 4 |
| 2022-10-06 | Immunovant, Inc.10% owner | Purchase | 416,667 | $6.00 | $2.5m | Form 4 |
| 2021-10-18 | Arbutus Biopharma Corp10% owner | ConversionSeries A participating convertible preferred shares | 1,164,000 | not reported | not reported | Form 4 |
| 2021-10-18 | Arbutus Biopharma Corp10% owner | Conversion | 22,833,922 | not reported | not reported | Form 4 |
| 2021-08-02 | Immunovant, Inc.10% owner | Other | 17,021,276 | not reported | not reported | Form 4 |
| 2020-09-17 | Immunovant, Inc.10% owner | Other | 8,773,969 | not reported | not reported | Form 4 |
| 2020-09-04 | Immunovant, Inc.10% owner | Purchase | 380,000 | $33.00 | $12.5m | Form 4 |
| 2020-05-12 | Immunovant, Inc.10% owner | Other | 8,773,969 | not reported | not reported | Form 4 |
| 2020-04-16 | Immunovant, Inc.10% owner | Purchase | 1,034,483 | $14.50 | $15.0m | Form 4 |
| 2019-12-18 | Immunovant, Inc.10% owner | OtherSeries A Preferred Stock, $0.0001 par value per share | 10,000 | $10.00 | $100.0k | Form 4 |
| 2019-12-18 | Immunovant, Inc.10% owner | Other | 36,919,967 | $10.00 | $369.2m | Form 4 |
| 2018-01-12 | Arbutus Biopharma Corp10% owner | PurchaseSeries A Participating Convertible Preferred Shares | 664,000 | $100.00 | $66.4m | Form 4 |
| 2017-10-16 | Arbutus Biopharma Corp10% owner | PurchaseSeries A Participating Convertible Preferred Shares | 500,000 | $100.00 | $50.0m | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 31, 2026, 00:00 ET. Listed shows no prices and gives no investment advice.